Reid W. Merryman, Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil, Sonali M. Smith, John M. Timmerman, Andrew D. Zelenetz, Meghan Gutierrez, Wendy Béguelin, Carla Casulo, James R. Cerhan, Michael R. Green, Brad S. Kahl, Robert Kridel, Brian K. Link, Matthew J. Maurer, Bertrand Nadel, Andrea J. Radtke, Efrat Luttwak, Gilles Salles, Laurie H. Sehn, Laura Pasqualucci, Ann S. LaCasce
ABSTRACT: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.